Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18417900 | 1-(NAPHTHALEN-2-YLOXY)-3-(PIPERIDIN-1-YL)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | January 2024 | August 2024 | Abandon | 7 | 0 | 1 | No | No |
| 18393813 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | December 2023 | February 2024 | Allow | 2 | 0 | 0 | No | No |
| 18488969 | 2-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | July 2024 | Abandon | 9 | 1 | 1 | No | No |
| 18473147 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | September 2023 | April 2024 | Allow | 7 | 1 | 0 | No | No |
| 18242641 | PYRIDO[4',3':4,5]PYRROLO[3,2-C][1,7]NAPHTHYRIDIN-10-ONE COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18242828 | PYRROLO[2,3-C][1,7]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18239113 | 1-(NAPHTHALEN-2-YLOXY)-3-(PIPERIDIN-1-YL)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | August 2023 | August 2024 | Abandon | 12 | 2 | 1 | No | No |
| 18238732 | NOVEL POTASSIUM CHANNEL INHIBITORS | August 2023 | April 2024 | Allow | 8 | 2 | 0 | No | No |
| 18453748 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18332849 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | June 2023 | April 2024 | Allow | 10 | 1 | 0 | No | No |
| 18331289 | LRRK2 INHIBITORS | June 2023 | January 2024 | Allow | 7 | 0 | 0 | No | No |
| 18319630 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | May 2023 | April 2024 | Allow | 11 | 0 | 0 | No | No |
| 18104691 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | February 2023 | May 2024 | Allow | 15 | 2 | 0 | No | No |
| 18161843 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | January 2023 | January 2024 | Allow | 12 | 1 | 1 | No | No |
| 18159798 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | January 2023 | April 2024 | Allow | 15 | 1 | 0 | No | No |
| 18093142 | PROCESS OF MAKING CFTR MODULATORS | January 2023 | June 2024 | Allow | 17 | 1 | 0 | No | No |
| 18093250 | SUBSTITUTED PYRIDINES AND METHODS OF USE | January 2023 | May 2024 | Abandon | 16 | 1 | 1 | No | No |
| 18087890 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | December 2022 | March 2024 | Allow | 15 | 0 | 1 | No | No |
| 18068852 | TREHALOSE ANALOGUES | December 2022 | August 2023 | Allow | 7 | 1 | 0 | No | No |
| 18066667 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | December 2022 | November 2023 | Allow | 11 | 1 | 0 | No | No |
| 18082401 | POLYPHENOLS DERIVATIVES | December 2022 | June 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18075316 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | December 2022 | May 2024 | Allow | 17 | 1 | 1 | No | No |
| 18061034 | PHOSPHONATE LINKERS AND THEIR USE TO FACILIATE CELLULAR RETENTION OF COMPOUNDS | December 2022 | August 2023 | Allow | 9 | 1 | 0 | No | No |
| 17983873 | METHOD OF PREPARING IONIC FLUIDS | November 2022 | August 2023 | Allow | 9 | 1 | 0 | No | No |
| 18053459 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | November 2022 | August 2023 | Allow | 10 | 0 | 1 | No | No |
| 17981887 | SALTS OF A PIM KINASE INHIBITOR | November 2022 | March 2024 | Allow | 16 | 0 | 1 | No | No |
| 17976150 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | October 2022 | January 2024 | Allow | 14 | 1 | 1 | No | No |
| 18050404 | CD73 COMPOUNDS | October 2022 | November 2023 | Allow | 12 | 1 | 0 | No | No |
| 18049802 | LRRK2 INHIBITORS | October 2022 | January 2023 | Allow | 3 | 0 | 0 | No | No |
| 18049052 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | October 2022 | June 2023 | Allow | 8 | 1 | 0 | No | No |
| 18048079 | FUSED PYRROLINES WHICH ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS | October 2022 | June 2023 | Allow | 8 | 0 | 1 | No | No |
| 17963939 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | October 2022 | October 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17959256 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | October 2022 | August 2023 | Allow | 10 | 0 | 1 | No | No |
| 17936973 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | September 2022 | February 2024 | Allow | 17 | 1 | 1 | No | No |
| 17935791 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | September 2022 | October 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17929505 | DEUTERATED COMPOUNDS AND USES THEREOF | September 2022 | July 2023 | Allow | 11 | 1 | 0 | No | No |
| 17929153 | SYNTHESIS OF NIROGACESTAT | September 2022 | July 2024 | Allow | 22 | 1 | 1 | No | No |
| 17820281 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | August 2022 | February 2024 | Allow | 18 | 1 | 1 | No | No |
| 17889300 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | August 2022 | January 2024 | Allow | 17 | 1 | 1 | No | No |
| 17888281 | Inhibitors of Tryptophan Dioxygenases (IDO1 and TDO) And Their Use In Therapy | August 2022 | June 2024 | Abandon | 22 | 2 | 0 | No | No |
| 17816232 | TEAD INHIBITORS AND USES THEREOF | July 2022 | October 2023 | Abandon | 14 | 0 | 1 | No | No |
| 17876958 | HETEROCYCLIC INHIBITORS OF PTPN11 | July 2022 | July 2023 | Allow | 12 | 1 | 0 | No | No |
| 17876433 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | July 2022 | July 2023 | Allow | 11 | 2 | 0 | No | No |
| 17870509 | COMPOUNDS AND METHODS FOR DETECTION OF SUPEROXIDE | July 2022 | March 2023 | Allow | 8 | 0 | 0 | No | No |
| 17858840 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | July 2022 | August 2023 | Allow | 13 | 1 | 0 | No | No |
| 17858712 | FUSED HETEROTRICYCLIC ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | July 2022 | May 2024 | Allow | 23 | 1 | 1 | No | No |
| 17852847 | METHOD FOR PREPARING MACITENTAN AND INTERMEDIATE COMPOUND THEREOF | June 2022 | April 2023 | Allow | 9 | 1 | 0 | No | No |
| 17809060 | COMPOSITIONS, SYSTEMS, AND METHODS FOR GENERATING INNER EAR HAIR CELLS FOR TREATMENT OF HEARING LOSS | June 2022 | October 2023 | Abandon | 15 | 0 | 1 | No | No |
| 17840712 | SUBSTITUTED PYRAZOLE AMIDES | June 2022 | January 2024 | Allow | 19 | 1 | 1 | No | No |
| 17831842 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | June 2022 | March 2023 | Allow | 10 | 0 | 0 | No | No |
| 17776513 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | May 2022 | January 2024 | Allow | 20 | 1 | 1 | No | No |
| 17738055 | Synthetic Intermediates for Novel Cannabinoids and Cannabinoid Acids and Their Derivatives | May 2022 | February 2023 | Allow | 9 | 0 | 0 | No | No |
| 17732447 | Benzimidazoles and Methods of Using Same | April 2022 | August 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17728852 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | April 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17690390 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | March 2022 | March 2023 | Allow | 12 | 0 | 0 | No | No |
| 17689665 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OSTEOARTHRITIS COMPRISING OBTUSIFOLIN, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | March 2022 | November 2023 | Allow | 21 | 2 | 0 | No | No |
| 17679775 | SILANOL BASED THERAPEUTIC PAYLOADS | February 2022 | November 2023 | Allow | 20 | 1 | 1 | No | No |
| 17679308 | HODGKIN LYMPHOMA THERAPY | February 2022 | May 2023 | Allow | 14 | 0 | 1 | No | No |
| 17609177 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | February 2022 | January 2024 | Allow | 27 | 1 | 1 | No | No |
| 17672351 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | February 2022 | June 2023 | Allow | 16 | 1 | 0 | No | No |
| 17634140 | PHOSPHINE REAGENTS FOR AZINE FLUOROALKYLATION | February 2022 | May 2023 | Allow | 16 | 1 | 0 | No | No |
| 17666465 | FORMULATION OF METAXALONE | February 2022 | July 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17665253 | Thermally Sensitive Protecting Groups for Cysteine for Peptide Cyclization and Selective Disulfide Bond Formation | February 2022 | April 2023 | Allow | 14 | 0 | 0 | No | No |
| 17629810 | Fibre Reactive Dyes, Their Preparation and Their Use | January 2022 | July 2023 | Allow | 17 | 0 | 0 | No | No |
| 17571839 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | January 2022 | July 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17560173 | PARASITE THERAPY | December 2021 | April 2023 | Allow | 16 | 1 | 0 | No | No |
| 17552577 | RAD51 INHIBITORS | December 2021 | December 2023 | Allow | 24 | 2 | 0 | No | No |
| 17617598 | A PROCESS FOR THE SYNTHESIS OF LOFEXIDINE | December 2021 | May 2022 | Allow | 5 | 0 | 0 | No | No |
| 17531660 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | November 2021 | December 2022 | Allow | 13 | 0 | 0 | No | No |
| 17611902 | METHOD FOR PREPARING DIHYDROARTEMISININ BULK DRUG IN SINGLE PROCESS | November 2021 | May 2024 | Allow | 30 | 0 | 0 | No | No |
| 17610548 | AGONISTS OF ROR GAMMAt | November 2021 | February 2024 | Allow | 27 | 0 | 0 | No | No |
| 17521031 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | November 2021 | June 2023 | Allow | 19 | 2 | 0 | No | No |
| 17521581 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | November 2021 | March 2023 | Allow | 31 | 2 | 0 | No | No |
| 17594693 | INTERMEDIATE OF ERIBULIN AND SYNTHESIS METHOD AND USE THEREOF | October 2021 | February 2024 | Allow | 27 | 0 | 2 | No | No |
| 17506261 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | October 2021 | March 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17451279 | PROCESS FOR PREPARING CYANOACETATES | October 2021 | July 2023 | Allow | 21 | 0 | 0 | No | No |
| 17503138 | PROCESS FOR THE CYCLOADDITION OF A (HETERO)ARYL 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | October 2021 | May 2024 | Allow | 31 | 3 | 1 | No | No |
| 17602401 | DEUTERATED ANTIMICROBIAL COMPOUNDS | October 2021 | February 2023 | Allow | 17 | 0 | 0 | No | No |
| 17495997 | PROCESS FOR THE MANUFACTURING OF (6AR,10AR)-7-PROPYL-6,6A,7,8,9,10,10A,11-OCTAHYDRO-[1,3]DIOXOLO[4',5':5,6]BENZO[1,2-G]QUINOLINE AND (4AR,10AR)-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDRO-BENZO[G]QUINOLINE-6,7-DIOL | October 2021 | April 2023 | Allow | 19 | 0 | 0 | No | No |
| 17496375 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | October 2021 | February 2023 | Allow | 16 | 1 | 0 | No | No |
| 17494552 | MANUFACTURING METHODS AND POLYMORPHS OF A THIAZOLINE ANTI-HYPERALGESIC AGENT | October 2021 | May 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17594090 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | October 2021 | March 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17599029 | FURAN SURFACTANT COMPOSITIONS AND METHODS | September 2021 | June 2022 | Allow | 8 | 0 | 0 | No | No |
| 17593812 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | September 2021 | November 2023 | Allow | 26 | 1 | 1 | No | No |
| 17481649 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | September 2021 | April 2023 | Allow | 19 | 1 | 0 | No | No |
| 17475559 | Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders | September 2021 | June 2023 | Allow | 21 | 1 | 1 | No | No |
| 17439069 | SMALL MOLECULE PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY | September 2021 | May 2023 | Allow | 20 | 0 | 1 | No | No |
| 17474631 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | September 2021 | April 2023 | Allow | 19 | 1 | 0 | No | No |
| 17469728 | Method for Controlled Release Using Mechanical Force | September 2021 | October 2022 | Allow | 13 | 1 | 0 | No | No |
| 17468048 | Thermally Sensitive Protecting Groups for Cysteine, and Manufacture and Use Thereof | September 2021 | October 2022 | Allow | 13 | 0 | 0 | No | No |
| 17460662 | PYRAZOLE COMPOUNDS AS LSD1 INHIBITORS AND APPLICATIONS THEREOF | August 2021 | September 2022 | Allow | 12 | 0 | 0 | No | No |
| 17458130 | Conversion of CBD to D8-THC to D6a10a-THC | August 2021 | February 2023 | Abandon | 18 | 1 | 0 | Yes | No |
| 17433999 | COMPOUND | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17407646 | COMPOUND AND FILM AND IR SENSOR AND COMBINATION SENSOR AND ELECTRONIC DEVICE | August 2021 | October 2022 | Allow | 13 | 0 | 1 | No | No |
| 17431284 | MANUFACTURING METHOD OF NITRILE COMPOUND | August 2021 | July 2023 | Allow | 23 | 0 | 0 | No | No |
| 17402932 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | August 2021 | January 2023 | Allow | 17 | 1 | 0 | No | No |
| 17431091 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | August 2021 | February 2024 | Allow | 31 | 0 | 0 | No | No |
| 17444947 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | August 2021 | April 2023 | Allow | 20 | 1 | 1 | No | No |
| 17398862 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | August 2021 | May 2023 | Allow | 22 | 0 | 2 | No | No |
| 17398902 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | August 2021 | October 2023 | Abandon | 26 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHTERENGARTS, SAMANTHA L.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SHTERENGARTS, SAMANTHA L works in Art Unit 1626 and has examined 1,580 patent applications in our dataset. With an allowance rate of 76.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 19 months.
Examiner SHTERENGARTS, SAMANTHA L's allowance rate of 76.0% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SHTERENGARTS, SAMANTHA L receive 1.17 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SHTERENGARTS, SAMANTHA L is 19 months. This places the examiner in the 91% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +12.5% benefit to allowance rate for applications examined by SHTERENGARTS, SAMANTHA L. This interview benefit is in the 53% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 37.4% of applications are subsequently allowed. This success rate is in the 82% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 64.9% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.0% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.5% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.2% of allowed cases (in the 45% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.